Table 2

Geometric mean ratio (90% confidence intervals) for fevipiprant 150 mg pharmacokinetic parameters with and without probenecid 1000 mg twice daily (pharmacokinetic analysis set)

Mixed-effects model with a fixed effect for treatment and a random effect for subject. Subjects with missing PK parameters for any treatment but not all treatments are included in the analysis assuming “missing” as random. Geometric mean ratios and 90% CI are back-transformed from log scale.

ParameterTreatmentnaAdjusted Geometric Mean (90% CI)ComparisonTreatment Comparison
Geometric Mean Ratio90% CI
AUClast (ng*h/ml)Fevipiprant163412 (2943–3956)Fevipiprant + probenecid vs. fevipiprant2.482.15–2.87
Fevipiprant + probenecid158466 (7278–9848)
AUCinf (ng*h/ml)Fevipiprant153537 (3022–4140)Fevipiprant + probenecid vs. fevipiprant2.552.17–2.99
Fevipiprant + probenecid159012 (7701–10547)
Cmax (ng/ml)Fevipiprant16722 (586–891)Fevipiprant + probenecid vs. fevipiprant1.671.33–2.10
Fevipiprant + probenecid151204 (970–1494)
CL/F (l/h)Fevipiprant1542.4 (36.2–49.6)Fevipiprant + probenecid vs. fevipiprant0.3920.335––0.460
Fevipiprant + probenecid1516.6 (14.2–19.5)
CLr (l/h)Fevipiprant169.7 (8.6–10.9)Fevipiprant + probenecid vs. Fevipiprant0.1200.106–0.136
Fevipiprant + probenecid151.2 (1.0–1.3)
  • a Number of evaluable subjects.